Moreover, it elucidates the mechanistic basis for the observed clinical benefits of ACE inhibitors in COPD/CHF patients and provides proof of principle for a novel HIF‐2α antagonism‐based therapeutic strategy. The gene discussed is EPAS1; the disease is chronic obstructive pulmonary disease.